MBNL1 identified as a potential cancer drug target for a type of childhood leukemia

Scientists from St. Jude Children's Research Hospital and collaborators person discovered that the RNA-binding macromolecule MBNL1 promotes the maturation of a signifier of puerility leukemia characterized by KMT2A cistron rearrangements. The uncovering identifies MBNL1 arsenic a promising therapeutic people for aboriginal cause development. The results were published August 7 successful Science Advances.